<code id='7C061A814D'></code><style id='7C061A814D'></style>
    • <acronym id='7C061A814D'></acronym>
      <center id='7C061A814D'><center id='7C061A814D'><tfoot id='7C061A814D'></tfoot></center><abbr id='7C061A814D'><dir id='7C061A814D'><tfoot id='7C061A814D'></tfoot><noframes id='7C061A814D'>

    • <optgroup id='7C061A814D'><strike id='7C061A814D'><sup id='7C061A814D'></sup></strike><code id='7C061A814D'></code></optgroup>
        1. <b id='7C061A814D'><label id='7C061A814D'><select id='7C061A814D'><dt id='7C061A814D'><span id='7C061A814D'></span></dt></select></label></b><u id='7C061A814D'></u>
          <i id='7C061A814D'><strike id='7C061A814D'><tt id='7C061A814D'><pre id='7C061A814D'></pre></tt></strike></i>

          
          WSS
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          entertainment